Peter DiLaura
Chief Executive Officer en Initial Therapeutics Inc .
Perfil
Peter DiLaura is currently the President, Chief Executive Officer & Director at Initial Therapeutics Inc. He is also a Director at Character Biosciences, Inc., an Executive-in-Residence at ShangPharma Innovation, Inc., and a Venture Partner at Lifeforce Capital Management, LLC.
In the past, Mr. DiLaura served as the President, Chief Executive Officer & Director at Second Genome, Inc. from 2012 to 2016.
He was also the Director of Business Development at Ventro Corp.
from 1999 to 2001.
Additionally, he held a position in business development at International Business Machines Corp.
Mr. DiLaura was a Strategic Advisor at SV Health Investors LLP from 2017 to 2019.
He was the Senior Vice President of Products & Marketing at Ingenuity Systems, Inc. in 2010.
He also served as an Advisor at Takeda Pharmaceutical Co., Ltd.
in 2017.
Furthermore, Mr. DiLaura worked as a Principal at Wilkerson Group and as the Chief Business & Strategy Officer at Sonoma Biotherapeutics, Inc. Mr. DiLaura completed his undergraduate degree at the University of Pennsylvania in 1995.
He also received an undergraduate degree from The Wharton School of the University of Pennsylvania in the same year.
Cargos activos de Peter DiLaura
| Empresas | Cargo | Inicio |
|---|---|---|
Lifeforce Capital Management, LLC
 Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | Private Equity Investor | - |
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultant / Advisor | - |
Character Biosciences, Inc.
 Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | Director/Board Member | - |
Initial Therapeutics Inc
 Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | Chief Executive Officer | 18/04/2024 |
Antiguos cargos conocidos de Peter DiLaura.
| Empresas | Cargo | Fin |
|---|---|---|
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Consultant / Advisor | 31/12/2019 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Consultant / Advisor | 31/12/2017 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Chief Executive Officer | 13/04/2016 |
Ingenuity Systems, Inc.
 Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Sales & Marketing | 31/10/2010 |
Ventro Corp.
 Ventro Corp. Information Technology ServicesTechnology Services Ventro Corp. provides e-commerce solutions. | Corporate Officer/Principal | 30/09/2001 |
Formación de Peter DiLaura.
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| IBM | Technology Services |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Empresas privadas | 10 |
|---|---|
Ventro Corp.
Ventro Corp. Information Technology ServicesTechnology Services Ventro Corp. provides e-commerce solutions. | Technology Services |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Ingenuity Systems, Inc.
Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Technology Services |
Wilkerson Group
 Wilkerson Group Medical/Nursing ServicesHealth Services Part of International Business Machines Corp., Wilkerson Group is a consulting private company that provides services to the pharmaceutical and medical products industry. The company is based in New York, NY. The company was founded by Kenneth D. Noonan. The CEO is Neil MacAllister. Wilkerson Group was acquired by International Business Machines Corp. on April 01, 1996. | Health Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | Finance |
Sonoma Biotherapeutics, Inc.
 Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Health Technology |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | Commercial Services |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Peter DiLaura
